Drugs / CD19/22 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07162571 | Jan 2026 → Dec 2030 expected | B-cell non-Hodgkin lymphoma, acute lymphoblastic leukemia | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/22 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07162571 ↗ |
| Modality | Cell therapy | “Locally manufactured second generation autologous CD19/22 CAR-T cells are used for immunotherapy.” NCT07162571 ↗ |